Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL +9.09%36 Debt-to-Equity is 0.48 as of Mar. 2026, which is 65% below its 10-year median of 1.37. GuruFocus rates BKK:EFORL with a GF Score™ of 36/100 and a GF Value™ of ฿0.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 99 Medical Distribution companies, E For L Aim PCL ranks worse than 50.51% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for E For L Aim PCL's Debt-to-Equity or its related term are showing as below:
BKK:EFORL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -60.4 Med: 1.37 Max: 14.96
Current: 0.48
During the past 13 years, the highest Debt-to-Equity Ratio of E For L Aim PCL was 14.96. The lowest was -60.40. And the median was 1.37.
BKK:EFORL's Debt-to-Equity is ranked worse than 50.51% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs BKK:EFORL: 0.48
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
E For L Aim PCL Debt-to-Equity Related Terms
E For L Aim PCL Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for E For L Aim PCL's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:EFORL vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, E For L Aim PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
E For L Aim PCL (BKK:EFORL) has a Debt-to-Equity of 0.48 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on E For L Aim PCL and its competitors. This is 65% below median its historical median of 1.37. According to the industry distribution chart, E For L Aim PCL ranks #50 out of 99 companies in the Medical Distribution industry, placing it in the top 50.5%.
Is E For L Aim PCL's Debt-to-Equity too high?
E For L Aim PCL's current Debt-to-Equity of 0.48 is 65% below median its 10-year median of 1.37. The Medical Distribution industry median Debt-to-Equity is 0.48. E For L Aim PCL's value of 0.48 is 0% at this industry median. Based on the distribution chart, E For L Aim PCL ranks #50 out of 99 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, E For L Aim PCL has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #50 out of 99 companies for Debt-to-Equity. This places E For L Aim PCL in the lower half of its industry. The industry median Debt-to-Equity is 0.48. E For L Aim PCL's value of 0.48 is 0% at this benchmark. While the company's 10-year median is 1.37 vs. the industry median of 0.48, E For L Aim PCL has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. E For L Aim PCL's current Debt-to-Equity of 0.48 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on E For L Aim PCL and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current Debt-to-Equity is 0.48, which is 65% below median its own 10-year median of 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.15, compared to a current price of ฿0.12 — trading 20% below its estimated fair value. The current Debt-to-Equity is 0.48, which is 65% below median its 10-year median of 1.37 and 0% at the Medical Distribution industry median of 0.48. E For L Aim PCL's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL), the current Debt-to-Equity is 0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 20% below its estimated GF Value™ of ฿0.15.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL:
Debt-to-Equity: 0.48 (65% below median its 10-year median of 1.37)
GF Value™: ฿0.15 vs. price of ฿0.12 (20% below fair value)
Industry Position: 0% at the Medical Distribution median (#50 of 99)
No single metric tells the full story. See the BKK:EFORL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
36GF Score
Get the complete analysis for BKK:EFORL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL has been successfully added to your 
